What is the appropriate preoperative management and surgical clearance for a 63-year-old man with a history of deep‑vein thrombosis who is taking Eliquis (apixaban) 5 mg twice daily?

Preoperative Management of Eliquis for Surgical Clearance

For this 63-year-old man on Eliquis 5 mg twice daily with a history of DVT, stop apixaban 1 day before low-to-moderate bleeding risk procedures (last dose the morning before surgery) or 2 days before high bleeding risk procedures, and do NOT use bridging anticoagulation. 1

Determining the Timing of Apixaban Interruption

The critical first step is classifying the surgical bleeding risk, as this directly determines when to stop Eliquis:

Low-to-Moderate Bleeding Risk Procedures

• Stop apixaban 1 day before surgery (skip the dose on the day of surgery) 1
• The FDA label specifies discontinuation at least 24 hours prior 2
• This applies regardless of whether the indication is DVT or atrial fibrillation 1

High Bleeding Risk Procedures

• Stop apixaban 2 days before surgery (last dose 48 hours pre-procedure) 1, 2
• The FDA label recommends at least 48 hours for moderate-to-high bleeding risk 2

Very High Bleeding Risk (Neuraxial/Intracranial)

• Consider extending interruption up to 5 days for procedures like spinal anesthesia or intracranial neurosurgery 3
• This is a critical safety consideration to avoid catastrophic bleeding complications

Key Management Principles

No bridging anticoagulation is recommended. This is a crucial point where practice has evolved—the 2022 CHEST guidelines explicitly state that bridging with heparin products is not indicated and actually increases bleeding risk without reducing thrombotic events 1, 3. This represents a major shift from older warfarin-era practices.

Renal function does NOT significantly affect apixaban timing (unlike dabigatran, which requires extended interruption with renal impairment). Apixaban's management is straightforward and doesn't require dose adjustment based on creatinine clearance for perioperative planning 1.

No routine laboratory monitoring is needed. The objective is avoiding high plasma concentrations during surgery, not achieving zero drug levels 3.

Postoperative Resumption

Resume Eliquis at least 6 hours after surgery once adequate hemostasis is established 3:

• For twice-daily dosing: restart the evening of surgery (if hemostasis adequate)
• If ongoing bleeding or surgical contraindication exists, delay resumption and consider mechanical VTE prophylaxis 3

The FDA label states to restart "as soon as adequate hemostasis has been established" 2, giving flexibility based on surgical assessment.

Common Pitfalls to Avoid

1. Do not bridge with LMWH or heparin—this outdated practice increases bleeding without benefit 1, 3

2. Do not confuse apixaban with dabigatran—dabigatran requires longer interruption periods and renal function adjustments; apixaban does not 1

3. Do not hold the drug for excessive periods—unnecessarily prolonged interruption increases thrombotic risk without added safety benefit

4. For neuraxial procedures, ensure adequate drug-free interval—the consequences of epidural hematoma are catastrophic 3

Documentation for Surgical Clearance

The patient is medically cleared for surgery provided:

• Apixaban is stopped according to the bleeding risk classification above
• No bridging anticoagulation is used
• The surgical team is aware of the DVT history for postoperative VTE risk stratification
• Plan for resumption is clearly communicated (typically evening of surgery or next morning if hemostasis adequate)

This evidence-based approach from the 2022 CHEST guidelines 1 represents the current standard of care and applies specifically to patients with VTE history like this patient, not just atrial fibrillation patients.